NWL · Newell Brands Inc. · Stock research

Current Thesis

The binary that gated this name resolved on 2026-07-31, and it resolved up. Q2 normalized EPS came in at $0.42 against a $0.20 consensus, net sales $1.994B against $1.978B, and management lifted the FY26 normalized EPS range to $0.73–$0.77 from $0.56–$0.60. The narrative leg an investor is buying is now specific: Newell printed core sales growth of +2.3%, its first quarterly increase in over four years, with normalized gross margin at 40.8% (+520bps YoY) and net leverage down to 4.8x from 5.5x. The complication sits inside the guide raise. The $0.17 midpoint increase matches the $0.17 per share of 2025 IEEPA tariff reimbursements recognized in the quarter; the underlying range was left at $0.56–$0.60. Ex-refund, Q2 adjusted EPS was roughly $0.21 versus $0.24 in Q2 2025. The tape has since gone quiet — the 2026-08-14 close of $6.24 sits 1.9% under the $6.36 52-week high with RSI(14) at 73.0 after a 65.7% three-month run, and the next company-scheduled report is not until late October.

Bullish and bearish views on Newell Brands Inc.

The model's bull view on Newell Brands Inc. (NWL), in brief: The inflection is measured, not projected. The bear view: The raise is tariff money. The FY26 normalized EPS guide went to $0.73–$0.77 from $0.56–$0.60, a $0.17 midpoint lift equal to the $0.17/share of 2025 IEEPA tariff reimbursements; the underlying range was held at $0.56–$0.60. Operating margin guidance is 10.0%–10.4% including the… Both cases follow in full.

Bull Case

• The inflection is measured, not projected. Q2 core sales +2.3% (2026-07-31 report) ended a streak of more than four years of declines; five of six business units grew and US net sales rose approximately 5%.
• Margin structure moved. Normalized gross margin 40.8%, +520bps YoY in Q2 2026 — SKU rationalization and mix are showing up in the P&L, not just in slideware.
• Deleveraging is quantified. Net leverage 4.8x at Q2 2026 versus 5.5x prior, against $5.0B total debt and $209M cash.
• The 2027 maturity is being taken out. On 2026-08-05 Newell priced an upsized $600M of 6.250% senior unsecured notes due 2031, closing expected 2026-08-19, with proceeds earmarked to redeem the 6.375% notes due 2027 in full.
• One desk is underwriting a much higher number. Canaccord Genuity maintained Buy and raised its target to $11 on 2026-08-03 — the outlier above a cluster that otherwise sits near spot.
• Full-year revenue guide moved up off the floor. FY26 sales guidance was raised to $7.276B–$7.348B from $7.204B–$7.348B, against a $7.287B consensus (2026-07-31).

Bear Case

• The raise is tariff money. The FY26 normalized EPS guide went to $0.73–$0.77 from $0.56–$0.60, a $0.17 midpoint lift equal to the $0.17/share of 2025 IEEPA tariff reimbursements; the underlying range was held at $0.56–$0.60. Operating margin guidance is 10.0%–10.4% including the tariff benefit and 8.6%–9.0% excluding it.
• Ex-refund earnings went backwards. Adjusted EPS stripped of the recoveries was approximately $0.21 in Q2 2026 versus $0.24 in Q2 2025.
• Q3 guidance does not extend the beat. Management guided Q3 adjusted EPS to $0.18–$0.20 against a $0.20 consensus and sales to $1.842B–$1.860B against $1.841B — an in-line-to-soft quarter with no refund flatter behind it.
• Three of four post-print targets sit at or below the last close. Citigroup Neutral PT $6 (2026-08-04), UBS Neutral PT $5.50 (2026-08-03), RBC Sector Perform PT $5 (2026-08-03). Against the 2026-08-14 close of $6.24, the sell-side base case has already been passed.
• An officer sold into the strength. A Form 4 dated 2026-08-06 shows Chief Legal & Administrative Officer Bradford Turner selling 100,000 shares at a weighted-average $6.16 (range $6.14–$6.19), leaving 433,398 shares held directly;
• The balance sheet still dominates the equity. $5.0B total debt against $209M cash and a market value quoted at approximately $2.1B on 2026-07-31 means the equity remains a thin residual claim, and the new paper prices at 6.250%.

Setup & Price Structure

• The narrative is maturing. The narrative's catalyst fired on 2026-07-31 and the sell-side repricing ran 2026-08-03 to 2026-08-04 (Canaccord $11, UBS $5.50, RBC $5, Citi $6). Everything dated since is housekeeping — the notes pricing on 2026-08-05 and the dividend declaration around 2026-08-12. Participation expanded and the story still works, but the incremental upgrade is spent: the highest-frequency desks now carry targets under the market price.
• Structure. The 2026-08-14 close of $6.24 is 1.9% below the $6.36 52-week high after a 65.7% three-month advance. Price has held the post-gap range for roughly two weeks without extending — consolidation at the top of the move, with no fresh high to confirm a second leg.
• Crowding observables, stated plainly. RSI(14) 73.0 at the 2026-08-14 close; short interest reported at 21.65% of float going into the 7/31 print; retail-facing coverage clustered on 7/31 and 8/3 ("Big Stocks Moving Higher" lists, an explicit short-squeeze headline); an insider selling 100,000 shares at $6.16 on 2026-08-06 into the first week of that strength.
• Downside references. The $5.00 shelf reclaimed in July was the pre-print structure and now coincides with RBC's 2026-08-03 target; UBS's $5.50 sits inside the 7/31 gap. Those two levels bracket where the post-print re-rating would be given back.
• A fresh entry at $6.24 is buying the top decile of a completed move with no company-scheduled event for roughly ten weeks. That is a low-conviction setup on timing, independent of whether the turnaround is real.

Catalyst Calendar (next 30 days)

• 2026-08-31 — Record date for the $0.07/share quarterly dividend declared on ~2026-08-12.
• ~2026-09-10 (est.) — Mid-September FINRA short-interest settlement publication; first clean look at whether the 21.65%-of-float short base has covered.
• 2026-09-15 — Dividend payable date, $0.07/share.
• ~2026-10-30 (est.) — Q3 2026 print. Outside the 30-day window and the next real binary: first quarter guided without a tariff-refund contribution, against an $0.18–$0.20 adjusted EPS range.

Elapsed catalysts

• 2026-08-19 — $600M 6.250% senior notes due 2031 offering closes; proceeds redeem the 6.375% notes due 2027. (passed 7d ago)

What Would Change Our Mind

The structural break is a give-back of the 7/31 gap. That move was built on a beat whose cash content was largely tariff recoveries plus a squeeze against 21.65% short interest; if the market reprices the quality of that beat, the gap is the path of least resistance and the $5.50–$5.00 zone (UBS and RBC targets, and the reclaimed July shelf) is where it lands. A weekly close below $5.50 would mark that repricing as underway and end the post-print leg. Separately, the thesis breaks on evidence rather than price if the Q3 report in late October shows core sales back in decline, or if management trims the FY26 range back toward the underlying $0.56–$0.60 it never raised. A third path: continued officer Form 4 selling with no offsetting open-market purchases, alongside the theme sliding to saturated as coverage stays retail-list-driven and no desk lifts a target above spot.

Correlation Notes

• Tariff-policy beta. The FY26 guide raise is a direct function of IEEPA reimbursements. Any judicial or executive change to the IEEPA tariff regime hits Newell's reported EPS mechanically and hits the same line at every importer that booked recoveries in 2026.
• Housewares and small-cap consumer complex. Trades with Helen of Troy, Spectrum Brands and Central Garden & Pet on shared shelf-space, promotional-intensity and freight variables; Benzinga's 2026-07-31 session note recorded consumer discretionary shares up 5.6% that day, the same session as the print.
• High-yield credit. At 4.8x net leverage with $5.0B of debt and fresh paper at 6.250%, the equity behaves as a levered call on the balance sheet; HY spread widening compresses it faster than the operating story can repair it.
• Short-squeeze cohort. With short interest reported at 21.65% of float into the print, the name moves with small-cap crowded-short flow rather than with staples-style consumer defensives.